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Abstract
Background: The process of malignant transformation, progression and metastasis of melanoma
is poorly understood. Gene expression profiling of human cancer has allowed for a unique insight
into the genes that are involved in these processes. Thus, we have attempted to utilize this
approach through the analysis of a series of primary, non-metastatic cutaneous tumors and
metastatic melanoma samples.
Methods: We have utilized gene microarray analysis and a variety of molecular techniques to
compare 40 metastatic melanoma (MM) samples, composed of 22 bulky, macroscopic (replaced)
lymph node metastases, 16 subcutaneous and 2 distant metastases (adrenal and brain), to 42
primary cutaneous cancers, comprised of 16 melanoma, 11 squamous cell, 15 basal cell skin
cancers. A Human Genome U133 Plus 2.0 array from Affymetrix, Inc. was utilized for each sample.
A variety of statistical software, including the Affymetrix MAS 5.0 analysis software, was utilized to
compare primary cancers to metastatic melanomas. Separate analyses were performed to directly
compare only primary melanoma to metastatic melanoma samples. The expression levels of
putative oncogenes and tumor suppressor genes were analyzed by semi- and real-time quantitative
RT-PCR (qPCR) and Western blot analysis was performed on select genes.
Results: We find that primary basal cell carcinomas, squamous cell carcinomas and thin melanomas
express dramatically higher levels of many genes, including SPRR1A/B, KRT16/17, CD24, LOR, GATA3,
MUC15, and TMPRSS4, than metastatic melanoma. In contrast, the metastatic melanomas express
higher levels of genes such as MAGE, GPR19, BCL2A1, MMP14, SOX5, BUB1, RGS20, and more. The
transition from non-metastatic expression levels to metastatic expression levels occurs as
melanoma tumors thicken. We further evaluated primary melanomas of varying Breslow's tumor
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genes suggesting that the "transition zone" represents a critical time for the emergence of the
metastatic phenotype. Several putative tumor oncogenes (SPP-1, MITF, CITED-1, GDF-15, c-Met,
HOX loci) and suppressor genes (PITX-1, CST-6, PDGFRL, DSC-3, POU2F3, CLCA2, ST7L), were
identified and validated by quantitative PCR as changing expression during this transition period.
These are strong candidates for genes involved in the progression or suppression of the metastatic
phenotype.
Conclusion: The gene expression profiling of primary, non-metastatic cutaneous tumors and
metastatic melanoma has resulted in the identification of several genes that may be centrally
involved in the progression and metastatic potential of melanoma. This has very important
implications as we continue to develop an improved understanding of the metastatic process,
allowing us to identify specific genes for prognostic markers and possibly for targeted therapeutic
approaches.
Background
In the United States, the overall incidence of melanoma is
increasing at a rate faster than any other cancer, with
recent estimates for the lifetime risk of developing inva-
sive melanoma at 1/49 [1]. Patients diagnosed with meta-
static melanoma (AJCC stage IV) have an overall poor
prognosis, and 6 out of every 7 deaths associated with all
types of skin cancer are caused by metastatic melanoma
[1-3]. Whereas patients with thin primary tumors are
cured after appropriate surgical intervention, most
patients with advanced disease do not respond to availa-
ble therapies, currently limited to only 2 FDA approved
agents to treat stage III and IV melanoma. For most can-
cers, earlier detection methods have the greatest impact
on survival and further contributing to better cure rates,
with targeted treatment regimens depending upon an
understanding of the molecular profile of a tumor. Simi-
larly, we must improve our understanding of the mecha-
nisms that lead to progressive and metastatic disease, as
this will most likely provide the greatest hope for patients
in reducing the number of deaths due to metastatic
melanoma (MM).
The development of melanoma begins with the malignant
transformation of normal human epithelial melanocytes
(NHEM) located within the basement membrane of the
skin. However, the exact cellular mechanisms that occur
and the genes and molecular pathways involved in this
process remain obscure. Early work has shown a direct
correlation between the thickness of the primary cutane-
ous melanoma (PCM) and its metastatic capacity, either
via the lymphatic system or hematogenously [4,5]. Once
melanoma has metastasized by either route, the overall
survival for patients greatly diminishes [6,7].
Many investigators have examined the differences
between primary melanoma and the late stage metastatic
disease. In the last few years, the power of microarray tech-
nology has been utilized to survey transcriptional differ-
ences that might provide insight into the metastatic
process [8-15]. The earliest reports used a handful of sam-
ples to first suggest that MM was characterized by a large
number of gene expression differences from cultured
melanocytes or benign nevi [8,16]. Since then, many
reports have corroborated this notion in principle,
although each study has focused on a different aspect of
the disease process. Some studies have used cell lines to
compare melanocytes to melanoma [8,12], while others
have utilized tissue samples to look at melanoma samples
relative to benign nevi or normal skin [10,11,15,16]. Sev-
eral studies have focused on the clinical aspects of the dis-
ease, attempting to identify gene expression signatures
that correlate with metastasis or survival [9,13,17-19].
Together, these studies suggest that many genes contribute
to the signature that is detectable in patients with MM. We
wished to further examine the exact timing of when these
gene expression patterns arise.
A few studies have begun to suggest that the metastatic
expression pattern emerges during the vertical growth
phase of primary melanomas. Initially, Smith et al. (2005)
[10] showed a distinct transition point of gene expression
change compared to normal skin, benign nevi, melanoma
in situ (MIS), PCM, and MM samples. However, they did
not specifically describe the Breslow's tumor thickness of
their primary melanoma samples. More recently, Soikkeli
et al. [19] in studying the draining lymph nodes for
melanoma, concluded that many of the "molecular traits"
of micrometastases were already present in primary
melanoma. The Melanoma Group of the European
Organization for Research and Treatment of Cancer
(EORTC) has recently reported that melanoma patients
with an average tumor thickness of 2.0 mm had a favora-
ble prognosis whereas patients with thicker tumors (5.3
mm) faired worse [13]. Although no comparisons were
made to patients with metastatic disease, this study
reported a 254-gene classifier that significantly correlated
with the metastatic dissemination of cutaneousPage 2 of 16
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ent primary tumors could be grouped based upon gene
expression.
In the current study, we have attempted to identify gene
expression patterns that segregate non-metastatic tumors
from MM, further examining thin PCM tumors to docu-
ment the emergence of the metastatic signature. Addition-
ally, we attempt to identify key genes involved in this
process, as opposed to those genes that simply document
the metastatic profile of a melanoma cell.
Methods
Tissue specimens
Over a 3 year period we surgically procured tumor sam-
ples from patients with primary cutaneous melanoma
(PCM), squamous cell carcinoma (SCC), basal cell carci-
noma (BCC) and metastatic melanoma (MM). All sam-
ples were obtained under an Investigational Review Board
(IRB) approved tissue procurement protocol
(MCC#13448, IRB#101751; PSM# 990914-JM, 020318-
JM). Upon surgical removal of the primary melanoma, a
single surgical oncologist (A.I.R.) utilized a scalpel to mac-
rodissect and procure a portion of each tumor, careful to
avoid central areas of necrosis and surrounding stroma.
With bulky melanoma tumors, macrodissection usually
results in the isolation of 90–95% pure tumor cells, with
little interdigitating stroma or other contaminating tis-
sues.
All samples for this study were confirmed to contain >
95% melanoma cells by a dermatopathologist. All sam-
ples were cryopreserved in liquid nitrogen and securely
de-identified through a centralized database. We analyzed
40 MM samples, composed of 22 bulky, macroscopic
(replaced) lymph node metastases, 16 subcutaneous and
2 solid organ metastases (adrenal and brain), and com-
pared them with 42 primary cutaneous cancers [16 PCM,
11 SCC, 15 BCC]. PCM consisted of 2 melanoma in situ
(MIS), 2 thin melanomas (< 1 mm), 3 intermediate-thick-
ness melanomas (1–4 mm), and 9 thick melanomas (> 4
mm). Additionally, we included 4 samples of normal
human skin and 1 sample of cultured, intermediate-pig-
mented, human epithelial melanocytes (NHEM).
RNA isolation, purification and hybridization
A portion of each cryopreserved tissue sample was dis-
solved in TRIzol® (Invitrogen, Carlsbad, CA), purified
according to manufacturer's recommendations, and fur-
ther purified on RNeasy columns (Qiagen Inc., Valencia,
CA). RNA integrity was verified by both gel electrophore-
sis and the Agilent 2100 Bioanalyzer (Agilent Technolo-
gies, Palo Alto, CA). A total of 5 ug of RNA was processed
using established Affymetrix protocols for the generation
of biotin-labeled cRNA and the hybridization, staining,
and scanning of arrays as outlined in the Affymetrix tech-
nical manuals [43,44]. The processed RNA was hybridized
to Human Genome U133 Plus 2.0 arrays from Affymetrix,
Inc. (Santa Clara, CA), and scanned on an Affymetrix
GeneChip® scanner 3000 at 2.5 μm resolution. A more
complete description of this process is available in Dob-
bin et al., 2005 [45]. The tissue samples were processed in
three independent groups.
Cell lines and tissue culture
Freshly excised melanoma samples were placed into cul-
ture media (RPMI 1640 and 5% FCS) and tissue procure-
ment and expansion of daughter cell lines was established
utilizing previously published techniques [46,47]. All cell
lines were passaged and expanded in vitro, utilizing RPMI
1640 and 5% FCS. All cell lines were split and passaged <
10 times and characterized by flow cytometry and cyt-
ospin preparations for cellular confirmation of melanoma
cell purity (data not shown). The cell lines, MCC77 and
MCC80a were derived from primary melanoma samples
with TC80b derived from a metastatic lymph node (from
the same patient). The cell lines, MCC12A and MCC12F,
were derived from 2 different subcutaneous melanoma
nodules from the same patient. There were 3 cell lines
examined from metastatic samples, MCC66C, MCC72
and MCC89. The NHEM were cultured according to the
manufacturer directions (Cambrex BioScience, Walkers-
ville, MD). Several cell lines were obtained from the
National Cancer Institute, Surgery Branch (624-Mel,
624.38-Mel and A375). These cell lines are derived from
patients with stage IV melanoma and are considered
highly aggressive cell lines by all standard measures of
analysis.
Real-time and semi-quantitative RT-PCR
First-strand cDNA synthesis was performed using Super-
script III RT (Invitrogen). Subsequently, the cDNA was
utilized for semi-quantitative PCR utilizing intron-span-
ning primers and optimized reaction conditions. We nor-
malized each sample with β-Actin as an internal control,
comparing each sample with AlphaEase®FC image analy-
sis software (Alpha Innotech, San Leandro, CA), followed
by densitometric analysis of the integrated values for each
sample. The expression levels of putative oncogenes and
tumor suppressor genes were analyzed by real-time quan-
titative RT-PCR (qPCR) using Assays-on-Demand Gene
Expression Assays (Applied Biosystems, Foster City, CA):
SPP1 (osteopontin, assay ID Hs00167093_m1), GDF15
(growth differentiation factor 15, assay ID
Hs00171132_m1), PITX1 (paired-like homeodomain tran-
scription factor1, assay ID Hs00267528_m1), DSC3
(desmocollin 3, assay ID Hs00170032_m1), CST6 (cystatin
E/M, assay ID Hs00154599), POU2F3 (POU domain, class
2, transcription factor 3, assay ID Hs00205009) and
GAPDH (assay IDHs99999905_m1) as the internal stand-Page 3 of 16
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quantitation values of a target template for each sample
were expressed as 2-ΔΔCt. Briefly, qPCR analysis was per-
formed utilizing 40 ng of total cDNA in a 25 μl reaction
volume (Applied Biosystems). We performed qPCR utiliz-
ing established techniques, with all samples performed in
triplicate and run on an ABI/PRISM 7500 Sequence Detec-
tor System (Applied Biosystems).
Gene microarray analysis and bioinformatics
MAS 5.0 analysis software was used to generate signal val-
ues for all probe sets based upon a mean intensity of 500,
subsequently exported and iteratively normalized as a
whole group to create the final normalization based upon
the most stable gene expression measurements across all
samples [48,49]. Genes highly expressed in metastatic
melanomas but not in PCM, BCC, and SCC, or the con-
verse, were specifically identified using visual inspection,
t-tests and Pearson's correlation [50] [see Additional file
1]. An initial set of 2,014 Affymetrix probe sets were iden-
tified to discriminate between metastatic tumor samples
and non-metastatic tumor samples and these were used
for clustering. The normalized probe set values were log2
transformed and "mean-centered" across all clustered
samples. Hierarchical clustering was then performed
using absolute correlation and complete linkage in Eisen's
cluster [51]. The complete microarray data is available
from the Gene Expression Omnibus website [52].
Significance Analysis of Microarrays (SAM) was per-
formed in order to identify a more extensive list of differ-
entially expressed genes expressed between PCM and MM
[53]. The first SAM analysis utilized all of the arrayed sam-
ples, with the MM samples opposed to all non-metastatic
samples, inclusive of BCC, SCC and normal skin. A sec-
ond SAM comparison utilized 6 thin PCM samples
opposed to 6 MM samples. The median false discovery
rate threshold was set at 5% for this comparison, with a
final gene list generated by intersecting the two resulting
gene lists. Following all microarray analyses, the identi-
fied probe sets were annotated based on the sequence of
the probes used on the arrays [54].
Western blot analysis
Whole cell extracts from PCM and MM cell lines were pre-
pared by directly lysing cells in SDS sample buffer. Expres-
sion of SPP-1 protein was assessed in cell lysate and
serum-free conditioned medium. Briefly, 4 × 106 cells
were plated in 5% FBS containing medium; 24 hours later,
the growth medium was replaced with serum-free
medium. The conditioned media and cell lysates were
harvested 24 hours later and resolved using a 12.5% SDS-
PAGE. Proteins were transferred to a PVDF membrane and
probed with the anti- human SPP-1 mouse monoclonal
antibody (Sigma, St. Louis, MO) (1:1000) followed by a
secondary antibody conjugated to horseradish peroxidase
(Amersham Biosciences, Piscataway, NJ) and detected
using chemiluminescence (Santacruz Biotechnology,
Santa Cruz, CA). The osteopontin band (SPP-1) was visu-
alized at ~55–65 kDa. Daughter melanoma cell lines
derived from the freshly procured melanoma samples
(with the exception of A375) were lysed by M-PER® Mam-
malian Protein Extraction Reagent (Pierce, Rockford, IL)
and processed according to manufacturer instructions. A
total of 15 μg of protein from each experimental condi-
tion were electrophoresed on 10% SDS-PAGE and trans-
ferred to nitrocellulose membranes (Bio-Rad, Hercules,
CA). Immunostaining was performed with the following
primary antibodies: DSC3 (Santa Cruz) 1:200; CLCA2
(Novus Biologicals, Littleton, CO) 1:500; PDGFRL
(Novus Biologicals) 1:500; α-tubulin (Cell signaling,
Danvers, MA), 1:1000. Immunocomplexes were visual-
ized using an enhanced chemiluminescence (ECL) West-
ern Blotting Substrate (Pierce). The intensity of the bands
were scanned with a Fujifilm intelligent dark box II and
analyzed with Fujifilm Las-1000 Lite V1.3 software.
Results
Gene expression differences between primary cutaneous 
cancer and metastatic melanoma
An initial training set of 23 tumors revealed 2,014 Affyme-
trix probe sets with a greater than 2-fold difference in the
average gene expression level between the MM and pri-
mary cutaneous cancers. This preliminary list, consisting
of 1,141 well characterized and 471 poorly characterized
human genes, was quite large, indicating a substantial dif-
ference between metastatic tumors and non-metastatic
tumors. The expression differences allowed for a relatively
robust gene classification of tissue samples into groups of
metastatic samples and non-metastatic primary tumors.
All tumor samples were clustered based on these gene
expression values and individually identified as metastatic
or non-metastatic based upon the characteristics of tumor
samples in the same cluster.
The initial set of samples comprised a training set for
which 22 of 23 samples were correctly partitioned into a
cluster containing primary melanoma or the cluster con-
taining MM samples. A single primary melanoma with a
Breslow's tumor thickness of 90 mm was misclassified as
a MM sample. We then analyzed and classified 2 inde-
pendent test sets comprised of primary skin cancer (BCC,
SCC and PCM) and MM samples, utilizing the same
genes. Co-clustering led to the correct identification and
classification of 56 of 60 melanoma samples. In general,
the misidentified samples were thick primary melanomas
classified as MM. Of note, several normal human skin
samples were analyzed and found to classify as non-met-
astatic by their gene expression profiles.Page 4 of 16
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ples that were misclassified, in order to generate a more
comprehensive list of genes that appeared to be differen-
tially expressed between MM and PCM using SAM. This
analysis identified 4,343 significantly different probe sets
again indicating that malignant melanoma tumors are
substantially different from the non-malignant tumors.
All defined probe sets had an average difference greater
than 2-fold between MM and PCM [see Additional file 2].
This list consisted of 1,667 Affymetrix probe sets that
detect 279 poorly defined transcripts, 114 minimally
defined genes, and 907 well characterized human genes.
From this list, 303 genes were highly expressed in MM
compared to 997 genes that were more highly expressed
in the non-metastatic primary skin cancers and normal
skin.
A subset of the full gene list is shown in Table 1, illustrat-
ing the trends in gene expression when MM samples are
compared to all primary cutaneous cancers (BCC/SCC/
PCM), or to only very early PCM (MIS/Thin), considered ≤
1.5 mm in Breslow's thickness for this analysis. We found
higher expression levels in MM for several genes impli-
cated or known as melanoma-associated tumor antigens
(MAGE, CSAG2) and some genes previously implicated in
melanoma progression (GDF15, MMP14, SPP-1), cell
cycle progression (CDK2, TYMS, BUB1) and the preven-
tion of apoptosis (BIRC5, BCL2A1). Among the 997 genes
with reduced expression in MM samples, several are
implicated in keratinocyte differentiation and epidermal
development, such as loricrin (LOR), involucrin (IVL), ker-
atin-5 (KRT5) and plakophilin (PKP1), suggesting a loss of
epidermal characteristics. The expression changes suggest
Table 1: Differential gene expression between metastatic melanoma and non-metastatic cutaneous tumors
Gene symbol Increase in metastatic melanoma relative 
to
Gene symbol Decrease in metastatic melanoma relative 
to
MIS/Thin BCC/SCC/MIS/Thin MIS/Thin BCC/SCC/MIS/Thin
MAGEA3/A6/A12 125/119/57 27/25/29 CALML5 193 228
MAGEA1/A2/A5 24/57/10 13/31/6 DSC1/3 186/64 198/71
CSAG2 76 36 PKP1 166 240
TRIM51 51 35 CLCA2 162 177
GDF15 30 47 DSG1/3 160/73 178/119
GYPC 18 14 LY6D 143 147
SPP1 15 7 SERPINB3/B5/B7 111/199/106 184/227/144
KIFC1 15 3 C19orf33 122 135
RGS20 14 14 FLG 112 112
C1orf90 13 15 KRT5/16/17 49/111/105 62/196/274
BCL2A1 12 12 KLK7/8/10/11 99/23/27/65 112/32/81/83
SOX5 15 8 LOR 95 98
SLC16A4 12 29 LGALS7 84 89
AKT3 11 9 CST6 82 56
PEG10 11 10 TRIM29 79 119
BUB1 14 3 SFN 77 125
RASGRF1 8 12 ASAH3 69 56
MMP14 8 6 GATA3 63 54
SPRED1 6 4 CBLC 60 64
GPR19 6 5 RAB25 59 78
CDK2 6 7 S100A14/A7/A7L1 27/57/21 44/60/82
HOXA10 3 4 ICEBERG 52 48
HOXB6/7/9 4/5/3 6/7/3 IVL 50 76
HEY1 7 16 ELOVL4 38 34
DUSP4 8 10 CXCL14 36 37
DUSP6 8 6 FOXN1 33 34
CDC45L 7 8 AQP3 29 31
CDC6 9 4 TP73L 29 48
RRM2 6 4 MUC15 25 21
TYMS 4 3 RORA 24 22
BIRC5 4 2 CD24 19 38
The initial statistical analysis addressed the question of whether there were genes differentially expressed (increased or decreased) between 
primary cancers (BCC/SCC/PCM) and metastatic cancers (metastatic melanoma). Column 1 (MIS/thin) are comprised of only such lesions, while 
column 2 (BCC/SCC/MIS/Thin) is comprised of all 4 histologic subtypes. All of the annotated genes listed above had a > 2-fold up- or down-
regulation in gene expression with the full names of each gene, accession number and gene identification provided in supplementary table 1. 
Abbreviations: MIS, melanoma-in-situ, BCC, basal cell carcinoma, SCC, squamous cell carcinoma, Thin, thin melanomas < 1.5 mm in Breslow's 
thickness.Page 5 of 16
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static and metastatic tumors, with genes putatively defin-
ing cellular function as it relates to the metastatic process.
A further analysis of the functional classes of genes
changed using the gene ontology revealed that 15 genes
associated with keratinocyte differentiation and 32 genes
involved in epidermis development were down-regulated
in the metastatic samples [see Additional file 3]. These
losses were complemented by the increased expression of
genes involved in several cellular processes, such as DNA
repair, protein transport, melanocyte differentiation,
muscle development, nervous system development and
carbohydrate metabolism. Table 1 further illustrates that
the magnitude of change in those genes under-expressed
was much greater on average than the level of change in
over-expressed genes. Overall, the losses in gene expres-
sion are both greater in number and magnitude compared
to the gains in gene expression in MM samples.
Identification of a transition point in gene expression 
between non-metastatic and metastatic tumor samples
Figure 1B displays the comparative gene expression levels
of 177 genes from our list across the spectrum of tissue
samples examined, revealing a consistent level of expres-
sion through all of the presumed "non-metastatic" sam-
ples (normal skin, BCC, SCC, MIS, Thin). A marked
change in the gene expression levels is seen, beginning
with the I.M. thickness PCM (average Breslow's tumor
thickness of 2.1 mm), progressively increasing or decreas-
ing to the expression level representative of MM lesions
and daughter MM cell lines. All of the thick PCM [average
Breslow's thickness 19 mm] exhibited gene expression
patterns similar to those of MM samples.
Comparative analysis of gene expression patterns in 
primary melanomas of different Breslow's thickness
The apparent transition zone for gene expression could
represent a critical time period where many tumorigenic
events occur simultaneously or may simply reflect the out-
growth of an aggressive and/or metastatic cell phenotype.
To address this issue, we evaluated the gene expression
levels in PCM of increasing Breslow's thickness and that of
MM samples. Table 2 (left columns) reveals the relative
change in gene expression for a subset of genes through-
out the spectrum of increasingly thick PCM and MM sam-
ples.
Several genes, such as the MAGE genes, exhibited a steady
and consistent increase in gene expression over the entire
range of tumor thicknesses. However, we found a single
major shift in expression for most genes when thinner pri-
mary tumors were directly compared to thicker ones. This
was most apparent when comparing I.M. thickness to
thick PCM, with the majority of genes showing the great-
est comparative increase in gene expression during this
period. Notable exceptions were genes such as SPP1,
HOXA10 and MMP14, for which the greatest differential
increase in expression was at the comparative interface
between thin and I.M. thickness tumor samples. Other
genes, such as MMP19, CTH, PDGFRL, C16orf34 and
GPR19, showed the greatest comparative increase in
expression when comparing MIS to thin PCM lesions.
We also found a similar phenomenon for genes with
decreased expression in primary tumors relative to more
advanced lesions (Table 2, right columns). Here, however,
the largest proportion of the gene expression change
occurred between thick PCM and MM samples. We found
very little expression of keratin (6B, 16, 17) and SPRR1 (A,
B) in MM compared to all primary melanomas, including
thick lesions. Several genes, such as TMPRSS4, STAR,
ST7L, HAS3, FGFR3, CASZ1 and HR, were found to have
gene expression changes at the very earliest stages of
tumor thickening. Together, the gene expression patterns
do not shift in a coordinated fashion as would be expected
as the result of the outgrowth of a clonal aggressive or
metastatic cell type. Rather, the data suggests that a series
of events occur as PCM tumors thicken that may ulti-
mately influence the expression of different groups of
genes. One limitation of this analysis is that only a few
tumor samples were evaluated at the intermediate thick-
nesses, which allows the possibility that some of the
observed differences might be tumor specific rather than
stage specific.
Comparative transcriptomic analysis of normal human 
epithelial melanocytes to primary and metastatic 
melanoma samples
We next compared the gene expression profiles of cul-
tured NHEM to PCM and MM samples (Table 3),
acknowledging the inherent limitations associated with
the comparisons of cultured cells and freshly procured
tumor samples [20]. We found large differences in gene
expression when comparing NHEM to early, non-meta-
static PCM (MIS/thin lesions only) and to MM samples
suggesting that PCMs are already quite different from
melanocytes. Genes such as KRT14, GJA1, S100A7,
S100A9, and EHF were higher in most melanomas while
genes such as CITED-1, GDF15, QPRT, OCA2, c-MET and
MME were more highly expressed in NHEM. Many of the
genes that increased (or decreased) in MM relative to thin
PCM could be attributed to a shift toward expression lev-
els similar to NHEM. For example, we found a decreased
expression of keratinocyte proteins such as loricrin and
involucrin. However, most of the melanoma associated
antigens, including the MAGE genes, PRAME, S100A8,
TRAG3 and MMP19, were more highly expressed in the
MM samples than in NHEM.Page 6 of 16
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Clinical primary and metastatic melanoma samples procured and cryopreserved at the time of surgeryFigure 1
Clinical primary and metastatic melanoma samples procured and cryopreserved at the time of surgery. A: Intraoperative illustrations of the spectrum of PCM 
and MM samples procured. The PCM represents varying tumor thicknesses, measured utilizing Breslow's depth of invasion. All procured lymph node metastases were macro-
scopically involved, often completely replacing the entire lymph node parenchyma. Distant metastatic (subcutaneous and solid organ) melanoma often exhibited varying degrees 
of pigmentation, however, surrounding stroma was avoided in procurement of melanoma samples. B: A distinct change in the gene expression patterns is apparent within the 
comparative groups of thin/I.M. to thick PCM samples. Gene over-expression (upper graph) is evident at the I.M. thickness sample set, with an average Breslow's tumor thickness 
of 2.1 mm and 19 mm for thick melanomas. Contrary, there is a decrease in gene expression (lower graph) of the same set of genes, with a comparative difference in gene down-
regulation evident at the same interphase of I.M. to thick PCM. Proceeding from left to right: normal skin, BCC, SCC, MIS, I.M., thick primary, metastatic melanoma (subcutane-
ous, lymph node and distant) and melanoma cell lines derived from patients with stage IV melanoma.
BMC Medical Genomics 2008, 1:13 http://www.biomedcentral.com/1755-8794/1/13Identification of putative oncogenes and tumor suppressor 
genes in melanoma
A perusal of the gene expression differences between PCM
and MM samples identifies numerous putative oncogenes
and tumor suppressor genes (TSG). Table 4 lists several of
the known oncogenes and TSG previously implicated in
tumor types. The gene with the largest increase in expres-
sion (13.2 fold) was osteopontin (SPP1). Although not pre-
viously identified as an oncogene, osteopontin expression
has been shown to strongly correlate with melanoma
invasion and tumor progression [21]. The lineage-specific
oncogene, MITF, previously shown to act as a master reg-
ulator of melanocyte development and a critical survival
oncogene amplified in melanoma, showed a 3.7 fold
increase [22-24]. Of the other listed genes, GDF15, c-Met
and the HOX loci have been shown to act as possible
oncogenes in breast cancer, squamous cell lung cancer,
prostate and pancreatic cancer. Several of the putative
melanoma TSGs have also been previously shown to con-
tribute to the development and progression of cancer in
other tumor histologies.
The shifts in gene expression occur at different stages of
the thickening process for each of the oncogenes and TSGs
listed in table 4. Some of the genes show a progressive and
steady increase (or decrease) in gene expression as tumors
of greater thickness are compared. For other genes, such as
SPP-1, GDF15 (putative oncogenes), PITX-1 and CST6
(putative TSG), the major shifts in gene expression appear
to occur at distinct but different times during the thicken-
ing of the primary melanoma tumors. This observation
suggests that these changes may occur spontaneously but
eventually may accumulate to contribute to the final met-
astatic phenotype.
Table 2: Comparative analysis of gene expression changes in primary and metastatic melanoma.
Gene 
Symbol
Relative increase in gene expression Gene 
Symbol
Relative decrease in gene expression
MIS to Thin Thin To IM IM to Thick Thick to Met MIS to Met MIS to Thin Thin To IM IM to Thick Thick to Met MIS to Met
MAGEA2 <2 8.6 9.4 3.1 30.7 SPRR1A <2 <2 <2 129.4 239.3
MAGEA3 <2 8.1 10.7 3 83.8 SPRR1B <2 <2 <2 52.8 100.8
MAGE A6 <2 7.1 9.8 2.7 103 KRT16 <2 <2 <2 68.3 195.5
MAGEA1,2 <2 2.5 8.9 2.6 81.5 KRT17 <2 2.6 <2 27.4 57.6
MAGE A1 <2 <2 11.1 <2 25.4 KRT6B <2 <2 <2 39.7 100.9
MAGE A5 <2 2.2 3.9 <2 11.7 AQP3 <2 <2 3.2 6.1 43.2
MMP19 5.4 <2 <2 <2 7.4 CD24 <2 <2 2 4.4 18.7
PDGFRL 22.3 3.6 <2 <2 6.3 FLG <2 <2 3 24.1 140
C16orf34 5.4 <2 <2 <2 18.5 IVL <2 2.2 <2 13.9 84.1
CTH 3.9 <2 <2 <2 8.8 KLK7 <2 <2 6.5 8.9 128
GPR19 4.2 <2 3 <2 23.9 LGALS7 <2 <2 3.4 17.3 109.3
SPP1 <2 13.1 <2 <2 44.9 LOR <2 <2 2.4 22.6 120.4
HOXA10 <2 3.3 <2 <2 3.8 RAB25 <2 <2 3.3 10.3 88.4
MMP14 <2 3.6 <2 2.1 9 SFN <2 <2 <2 10.6 24.2
AKT3 <2 <2 7.5 <2 14.3 C19orf33 3.1 <2 4.6 13.3 220.3
BCL2A1 <2 2.2 4.8 <2 18.7 ASAH3 <2 <2 25.9 <2 60
BIRC5 <2 <2 3.7 <2 3.4 KRT15 <2 <2 27.1 2.2 104.9
BUB1 <2 <2 9.4 <2 10.8 ELOVL4 <2 2.3 14.7 <2 41.9
CDC45L <2 <2 13 <2 9.1 GATA3 2.5 <2 14.3 <2 23.5
CDK2 <2 <2 4.8 <2 8.4 MUC15 <2 2.2 11.9 <2 25
CSAG2 <2 <2 19.6 2.6 54.5 SCEL <2 <2 28.8 <2 71.8
DUSP4 2 <2 5.7 <2 12.5 TP73L <2 <2 5.5 3.4 41.2
DUSP6 <2 <2 3.7 <2 10.5 RORA <2 <2 6.2 2.2 26.6
GYPC <2 <2 12.2 <2 14.2 POU2F3 <2 <2 13.9 2.2 73.9
HEY1 <2 <2 5.7 <2 9.3 ICEBERG <2 2.7 6.7 4.5 32.3
KIFC1 <2 <2 10.4 <2 16 CASZ1 <2 4.8 2.8 <2 12.3
PEG10 <2 2.4 4.1 <2 11.3 HR <2 3.7 <2 <2 7.7
RASGRF1 <2 <2 5.1 <2 9.9 TMPRSS4 8.7 <2 <2 3.1 42
RGS20 3.4 <2 9.2 <2 34.3 STAR 4.9 <2 <2 <2 11.1
SLC16A4 <2 <2 4.4 <2 26.4 ST7L 4.3 <2 3.6 <2 8.4
SOX5 <2 <2 12.3 <2 19.8 LTB4R 4 <2 2.3 <2 9.9
TRIM51 <2 3.1 15.9 <2 63.6 HAS3 4.9 <2 <2 2.5 16.6
TYMS <2 <2 3.6 <2 4.7 FGFR3 3.9 <2 3.2 <2 7.6
NOTE: All annotated genes listed above with a < 2 indicates that any difference between tumors for each comparative analysis was less than 2-fold. 
Underlined numbers indicate the greatest change in gene expression across varying PCM tumor thickness for each gene. Abbreviations: MIS, 
melanoma-in-situ, Thin, thin melanomas < 1.0 mm in Breslow's thickness, I.M., intermediate thickness between 1–4 mm, with thick melanomas > 4 
mm. PCM, primary cutaneous melanoma.Page 8 of 16
(page number not for citation purposes)
BMC Medical Genomics 2008, 1:13 http://www.biomedcentral.com/1755-8794/1/13Validation of select candidate genes by semi- and 
quantitative RT-qPCR analysis
To further validate the expression of putative TSG and
oncogenes in our melanoma panel, RT-qPCR was per-
formed on 20 previously arrayed samples, comprised of 7
PCM and 13 MM samples. Figure 2A shows an overall
decreased level of mRNA expression of TSG and increased
mRNA expression of oncogenes compared to normal skin.
This was consistent for all PCM samples compared to MM,
although not statistically significant when comparing
across Breslow's thicknesses. We then re-examined and
compared the RT-qPCR data to the microarray data in
order to validate the overall degree of agreement, finding
a significant correlation for all TSG and oncogenes exam-
ined (Figure 2B).
Utilizing semi-quantitative PCR analysis, we also exam-
ined several primary and MM daughter cell lines derived
from the freshly procured melanoma samples, normal
skin and NHEM for oncogene and TSG mRNA expression
(Figure 3A). Consistent with the data obtained from
microarray analysis, several of the melanoma derived cell
lines exhibited high levels of expression for several of the
reported oncogenes and a higher percentage of loss of
TSG. Overall, we found a favorable correlation between
the microarray results and both quantitative and semi-
quantitative PCR analysis for daughter and non-daughter
primary and MM cell lines.
Validation of gene expression and protein translation of 
select candidate genes by Western Blot analysis and 
immunohistochemistry
To independently verify and validate the gene expression
changes at the protein level, we studied several suspected
oncogenes and TSG for protein expression by Western
Blot analysis. Osteopontin (SPP1) protein expression was
examined from melanoma cell lysates and conditioned
cell free media derived from 2 primary and 6 MM daugh-
ter cell lines (Figure 3B, a, b). Interestingly, the protein
expression level of 2 subcutaneous MM nodules
(MCC12A, 12F) procured from the same patient greatly
differed. Similarly, we examined 2 paired cell lines
(MCC80a from a primary melanoma from a synchronous
metastatic lymph node, MCC80b), showing a slight
increase in SPP1 protein expression in the latter. Several
other melanoma cell lines exhibited minimal SPP1 pro-
Table 3: Comparative transcriptomic analysis of normal human epithelial melanocytes to thin primary cutaneous and metastatic 
melanoma samples
Fold Higher Expression in Melanoma Fold Lower Expression in Melanoma
Gene Symbol NHEM c/t 
MIS/Thin
Gene Symbol NHEM c/t 
Metastatic 
Melanoma
Gene Symbol NHEM c/t 
MIS/Thin
Gene Symbol NHEM c/t 
Metastatic 
Melanoma
KRT14 6787 GJA1 759 MME 106 MAP4 20
GJA1 5929 SEPP1 338 CITED1 77 OCA2 10
EHF 5487 KRT14 306 GDF15 64 TRIM7 7
SCEL 3931 MAGEA2 301 PAEP 47 CITED1 6
CLCA2 3689 TRAG3 242 RPEL1 45 TRPM4 6
S100A7 3609 EHF 193 HES6 43 MME 5
KRTDAP 3416 S100A9 160 ESDN 37 TRAP150 5
DSC1 2782 S100A7 129 QPRT 35 FER1L3 4
GJB6 2576 SCEL 126 OCA2 19 QPRT 4
CXCL14 2484 SLC22A3 125 RENBP 17 KLF8 4
LOR 2308 EPHA3 124 NR4A3 16 RPEL1 4
KRT6A 1989 KRTDAP 121 Siat7c 16 PACE4 4
PKP1 1835 S100A8 120 C6orf168 15 HPCAL1 4
SERPINB3 1778 ZIC1 119 BCL2A1 14 ACTR1A 4
S100A9 1768 CXCL14 118 NTT73 14 MET 3
KRT15 1545 IL18 108 PSCD3 14 RAB32 3
GATA3 1347 PRAME 102 HPCAL1 13 TYR 3
PPL 1339 MAGEA6 94.7 MET 12 IRF6 3
IMUP 1250 PLCB4 88 ALS2CR3 12 GDF15 3
ICEBERG 1123 CLCA2 87 PTPLA 12 HINT3 3
KRT6B 1114 GJB6 85 TBC1D7 11 SLC30A1 3
CSTA 693 MAGEA3 84 OA1 11 TRPV2 3
CST6 687 MMP19 59 TYR 11 RSN 3
NOTE: Abbreviations: NHEM: Normal Human Epithelial Melanocytes, c/t: Compared to, MIS, melanoma-in-situ, Thin, thin melanomas < 1.0 mm in 
Breslow's thicknessPage 9 of 16
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rable findings noted between melanoma cell lysates and
conditioned cell media.
Analysis of suspected TSG in 3 PCM and 3 MM cell lines
revealed a very low level of protein expression of DSC3 in
6/6 cell lines (3c) with 4/6 (2/3 primary and 2/3 MM) cell
lines expressing the protein for CLCA2 (3d). Interestingly,
we found PDGFRL protein expression in a single primary
cell line, with no evidence of expression in any of the met-
astatic cell lines (3e). Lastly, we chose to utilize existing
databases that have previously determined the cellular
staining patterns utilizing immunohistochemistry in skin
and melanoma samples, available for viewing at the
Human Protein Atlas website [55]. This website also high-
lights those available genes with available immunohisto-
chemical staining patterns of both primary and MM
samples [see Additional file 2].
Discussion
In this study, we have examined the gene expression pro-
files of a number of cutaneous tumors with the intention
of highlighting the differences between metastatic tumors
and non-metastatic tissues. We have profiled normal skin,
melanocytes, BCC, SCC, and early stage melanomas to
establish a gene expression pattern associated with the
non- metastatic state. It is well known that BCC and SCC
have little if any metastatic potential, and thus adding
such specimens substantially contributed to the overall
validity of our "non-metastatic" gene signature. Likewise,
similar findings are noted for MIS lesions and very early
primary melanomas (< 0.75 mm in Breslow's depth).
Opposed to this is the metastatic state, which exhibits
vastly different expression levels in thousands of genes
and is observed in thick PCM and MM tumors. The prin-
cipal finding of this study is that normal tissues and non-
metastatic cutaneous tumors can be distinguished from
metastatic melanoma tumors on the basis of the expres-
sion level of these genes. We have reported 1,300 tran-
scripts that differ in expression between thin PCM and
MM, many of which differ more than 100-fold. This
robust signature suggests that gene expression may be use-
ful for identifying metastatic potential in PCM tumors.
A number of previous studies have attempted to use gene
expression signatures to identify the genes associated with
the establishment or identification of metastatic tumors.
Using cell lines it has been shown that normal melano-
cytes differ greatly from tumor derived cells [8,12]. Benign
nevi have been shown to differ from thick or metastatic
melanoma tumors [10,11]. Also, several recent studies
have shown that MM or thicker melanoma tumors con-
Table 4: Differential expression of putative tumor oncogenes and suppressor genes in melanoma
Oncogenes
Gene Fold Increase Interval of Increase Activating Mechanisms in other 
Tumor Histologies
Affected Tumor Types
SPP-1 13.2 Thin to IM C-Met activation via αvβ3 receptor; 
Inhibition of apoptosis
Breast, HCC, Prostate, CRC, Head & 
Neck
MITF 3.7 Progressive increase Somatic alteration via gene amplification 
(Chr.#3p13-3p14)
None, Lineage Specific for Melanoma
CITED-1 (cbp/p300 
transactivator)
12.4 IM to Thick Activation of Stat-3, Ras/MAPK kinase 
signaling via Ets1, Ets2
Thyroid
GDF15 (PLAB) 22.7 IM to Thick Lineage specific activation or repression of 
ERK1/2; Integrator of AKT pathway
Breast, CRC, Gastric, Prostate, 
Pancreatic
c-Met 14.5 Thick to Met Ras-Associated Protein (Rap1)/ERK/MAPK, 
rac1, Grb2, PI3K, src activation
CRC, Breast, Ovarian, Pancreatic, 
Liver
HOX Locus (A3, A10, B6, B7, 
B13)




Gene Fold Decrease Interval of Decrease Suppressor Mechanisms in other 
Tumors Histologies
Affected Tumor Types
PITX-1 13.9 Thin to IM Ras Pathway (RASAL1) Barrett's [Esophagus] Prostate, 
Bladder
CST6 (CST E/M) 66.7 IM to Thick Hypermethylation Breast, Glioma
PDGFRL 7.3 IM to Thick Gene Deletion from Chr.# 8p21.3-p22 HCC, CRC, NSCLC
DSC3 42.8 Progressive decrease Hypermethylation Breast
POU2F3 49 Thin to IM Hypermethylation Cervical
CLCA2 162 MIS/Thin to MM Hypermethylation Breast
Note: Tables represent a partial list of identified tumor oncogenes and tumor suppressor genes (TSG's) in PCM and MM samples. The fold increase represents the greatest 
fold change noted throughout all comparisons of each PCM tumor thickness to MM. The activating/suppressive mechanism and affected tumor type are also identified. 
Abbreviations: HCC, hepatocellular carcinoma, CRC, colorectal carcinoma, NSCLC, non-small cell lung cancer, SCLC, squamous cell lung cancer, AML, acute myelogenous 
leukemia.Page 10 of 16
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Comparative gene expression analysis of putative oncogenes and tumor suppressor genesFigure 2
Comparative gene expression analysis of putative oncogenes and tumor suppressor genes. A: Comparative gene expression analysis utilizing qPCR data of putative 
tumor suppressor genes (CST6, DSC3, PITX1, POU2F3) and oncogenes (GDF15, SPP-1) in PCM (n = 7) and MM (n = 13) samples. Relative quantitation of target gene expres-
sion for each sample was determined using the equation 2-ΔΔCt, where GAPDH was used as the internal reference and normal skin as the calibrator. Values were Log base 10 
transformed (y-axis) so that all values below zero represent a down-regulation in gene expression and values above zero represent an up-regulation in gene expression, com-
pared to normal skin. B: Correlative microarray analysis of gene expression levels in primary and metastatic melanoma samples compared with normal skin. The statistical differ-
ences of gene expression between primary (PCM) and metastatic melanoma (MM) samples were analyzed by Wilcoxon's signed rank test; two-tailed significance level was set at 
α = 0.05. Compared to PCM samples (n = 7), the expression levels of 4 putative tumor suppressor genes (CST6, p < 0.0001; DSC3, p < 0.0001; PITX1, p = 0.0043, POU2F3, p 
< 0.0001) were significantly decreased in MM samples (n = 40), while the expression of putative oncogenes (GDF15, p = 0.0027; SPP1, p < 0.0001) were significantly increased in 
MM samples.
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Semi-quantitative RT-PCR analysis of oncogene and tumor suppressor genesFigure 3
Semi-quantitative RT-PCR analysis of oncogene and tumor suppressor genes. A: A panel of 12 putative oncogenes 
and 6 TSG were analyzed, with the relative levels of mRNA expression as follows: negative band (-), faintly visible band (+/-), 
visible band (+), strongly visible band (++), N = Not Done. β-actin served as the internal comparative control. The grey values 
of PCR products of each gene are analyzed by the AlphaEase 3 software and standardized according to β-actin in every sample. 
B: a, b, Daughter melanoma cell lines secrete SPP1 (osteopontin). The melanoma cell lysates and conditioned cell-free media 
was resolved by SDS-PAGE and transferred to a PVDF membrane. The blot was probed with anti-SPP1 antibody. c-f, Antibod-
ies for DSC-3 (c), CLCA2 (d), PDGFRL (e) and α-tubulin (f) as an internal control. Lanes 1–3 are PCM and lanes 4–6 are MM 
cell lines.
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the more aggressive phenotype with respect to clinical
outcome [9,13,14,17-19]. Although each of these studies
was unique in the samples they used and the gene expres-
sion signatures they report, we believe there is a very high
degree of similarity between all of the "signatures".
The recent report by Jaeger et al. coincides very well with
the current study [14]. Although they compared tumors to
normal skin they utilized U133A arrays from Affymetrix,
which contain a subset of the same probes found on the
U133 Plus 2.0 arrays used in the present study. We com-
pared the common probe sets of both arrays, finding a
65% overlap between the two gene lists. This is an exceed-
ingly high level of concordance between different micro-
array studies utilizing tumor samples; probably reflecting
the fact that the two studies used nearly identical microar-
ray platforms.
There remains considerable debate in the literature as to
why comparative microarray studies do not completely
coincide with each other. We believe that the primary rea-
son for such discrepancies is that strict p-values and other
restrictive criteria are often utilized to generate gene lists.
If we relax our criteria only slightly to generate a larger list
than reported in supplementary table 1, we find a stun-
ning 90% concordance with the study of Jaeger et al. The
remaining differences between the two studies appear to
be a few differences that exist between normal skin and
metastatic melanoma rather than between primary
melanoma and metastatic melanoma and a few genes that
exist within a small subset of melanoma tumors and
therefore most likely reflect subtle differences in the spec-
trum of tumors analyzed by the two studies (based on our
data).
In all of the recent gene expression studies an attempt has
been made to compare normal, benign, or non-metastatic
cells or tissues to clinically aggressive tumors. In most of
these studies, it is not clear where the shift in gene expres-
sion occurs. However, in the current study, we used a
larger number and variety of non-metastatic tissues to
illustrate the fact that the metastatic signature is robustly
different from all the non-metastatic conditions that one
might use for comparison. We have also included a docu-
mented gradation of tumor thicknesses to better resolve
thin primary melanomas from thick primary melanomas
which has helped to illustrate that the metastatic signature
emerges as primary melanoma tumors thicken.
We have approximated what might occur in an individual
tumor by grouping the melanoma samples into sub-
groups from thin through thick and proceeding on to met-
astatic tumors (Figure 1B). This illustration follows the
analysis of Smith et al. [10] who compared normal skin,
benign nevi, melanoma in situ (MIS) and MM samples to
show a distinct transition point of gene expression associ-
ated with the vertical growth phase of melanoma tumors.
However, that study did not specifically describe the Bres-
low's tumor thickness of their primary melanoma samples
leaving open the question of what was metastatic and
what was a non-metastatic tumor sample. We believe that
our data resolves this issue, showing that MIS and thin
melanomas do not have much, if any, of the gene expres-
sion measures associated with metastasis. The metastatic
signature emerges when primary melanomas begin to
thicken. This data suggests that thickening tumors is the
best arena for further evaluating the cellular changes lead-
ing to metastasis.
Thin melanomas are the most difficult samples to acquire
in a research setting where RNA integrity can be preserved
and thus our analysis is limited by the few samples of thin
melanoma we were able to collect during this study. Thus,
it is probable that we have not identified the optimal pro-
gression in the transition from non-metastatic gene
expression to metastatic gene expression. However, by
looking more closely at the various thicknesses of tumors,
we observed that the gene expression changes do not
occur synchronously. Certain changes occur early and
others appear later in the progression from thin to thick
tumors (Table 2). Each change brings the expression pat-
tern of primary melanoma tumors closer to the expression
pattern observed in metastatic tumors. This suggests that
the phenotype of tumors becomes more metastatic-like as
the tumor gets thicker and argues against the outgrowth of
a cell with the full metastatic signature.
Our data also indicates that many phenotypic changes
may be occurring during this thickening period. Our gene
ontology analysis suggests a fundamental shift in the
functional properties of the cells comprising a tumor.
There is a reduced expression or loss of genes involved in
the processes of keratinocyte differentiation, epidermal
development, cell adhesion and cell-to-cell signaling. This
loss of cell-stromal interactions may reflect the gain of
migratory potential for the metastatic cell type. This is
opposed by functional gains associated with the increased
expression of genes involved in melanocyte differentia-
tion, nervous system development, protein transport, car-
bohydrate metabolism and DNA repair. The
unidirectional shift in these classes of genes, the number
of genes involved, and the extent to which each gene
changed (fold-changes of 30 or more) all suggest a devel-
opmental change, rather than a regulation of cellular
metabolism. Further supporting such a fundamental
change is the observation by Alonso et al. that an epithe-
lial-mesenchymal transition occurs as the metastatic sig-
nature emerges [18].Page 13 of 16
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sion of putative proto- oncogenes and decreased expres-
sion of putative TSGs occurs (Table 3). Although most of
these oncogenes and TSGs have not been demonstrated to
function in melanoma progression, they represent key fac-
tors to consider when understanding the emergence of the
metastatic phenotype. Growth differentiation factor-15
(PLAB\MIC-1\GDF-15) shows a striking correlation
between expression level and metastatic phenotype in sev-
eral tumor types [25,26]. Osteopontin (SPP-1) is a
secreted phosphoglycoprotein that has been implicated in
tumor progression and invasive behavior in many tumor
types [27]. SPP-1 expression has been strongly correlated
with invasive melanoma but found highly expressed in
only 72% of invasive primary melanomas [21]. Our data
shows that SPP-1 gene expression increases when thin pri-
mary melanomas thicken (Table 2) and that SPP-1 is
expressed in daughter melanoma cell lines and secreted as
a soluble protein (Figure 2). Other identified genes, such
as Cbp/p300-interacting transactivator (CITED-1), hepatocyte
growth factor receptor (c-MET), and various homeobox
genes have yet to be investigated in melanoma although
some have been previously identified in metastatic
melanoma [11].
The TSGs listed in table 3 have been implicated in the evo-
lution of the metastatic state via down-regulation and
inactivation. PITX-1 has been identified as a TSG in sev-
eral tumor types, including lung cancer and Barrett's
esophagus leading to esophageal adenocarcinoma [28-
30]. Loss of PITX-1 expression is seen in thin primary
melanoma samples, with a 14-fold decrease in gene
expression in thin primary compared to I.M. samples.
Many of the other TSGs listed in table 3 have been down-
regulated by epigenetic silencing in other tumor histolo-
gies [31-38]. Recently, Muthusamy et al. described the epi-
genetic silencing of novel tumor suppressors in
melanoma samples, identifying 17 genes not previously
known to be hypermethylated. [39]. We have found 2
genes that are in common with this list. We are actively
examining the identified TSGs for evidence of epigenetic
silencing via hypermethylation of promoter CpG islands.
We also found several known melanoma tumor antigens
(MAGE, TRAG3, PRAME) highly expressed in thicker
tumors. This is consistent with studies that have shown an
increase in tumor antigen expression with advanced dis-
ease [8,40-42]. Some of these antigens were seen in nearly
all tumor samples while others were only seen in a subset
of the melanoma tumors. Nonetheless, these surface anti-
gens provide a mechanism for identifying the metastatic
cell arising in early melanoma tumors.
Based upon their distinct gene expression profiles, the
four classes of tumors could be correctly classified greater
than 90% of the time. The major difficulty in classification
was for thick primary melanoma tumors that appeared to
have the gene expression signature of MM tumors. The dif-
ficulty in classifying these tumors suggested that they
might represent a transitional state between primary
tumors and truly metastatic tumors. If we accept this
assumption, then 81 of our 82 tumor samples were cor-
rectly classified based upon their gene expression signa-
ture. With the ability to correctly and accurately classify
tumors into distinct classes, we can begin to investigate
the mechanisms responsible for malignant tumor forma-
tion, invasion, progression and metastasis.
Conclusion
Based upon our molecular analysis of primary cutaneous
(BCC, SCC, PCM) and MM samples, we conclude that
PCM and MM have distinct gene expression profiles that
may be useful for tumor tissue classification. Additionally,
squamous cell and basal cell carcinomas share certain
gene expression patterns with primary melanomas that
are distinct from MM. This is important to try and develop
prognostic markers for patients based upon the distinct
molecular profile of their melanoma, further able to dis-
tinguish between a metastatic versus non-metastatic gene
profile. This will allow for the physician and patient to
have a more informed discussion as to how to proceed
with clinical treatment options based upon the gene
expression profile.
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